Navigation Links
Shellpak® Demonstrates Statistically Significant Improvement in Patient Medication Adherence

RICHMOND, Va., June 16, 2011 /PRNewswire/ -- According to new data published in Clinical Therapeutics, the way a medication is packaged can have a significant impact on whether patients take it as prescribed. The study showed that Shellpak® calendar blister packaging from MeadWestvaco Corp. (NYSE: MWV), a provider of pharmaceutical packaging solutions, was associated with improvement in prescription adherence behavior in patients when compared with traditional pill vials. According to the researchers, a Shellpak-based adherence strategy could provide a substantial cumulative public health benefit when broadly implemented over a large population.

Poor adherence to medication is a growing issue across the country. The New England Healthcare Institute estimates the current cost of drug-related morbidity, including poor adherence, to be as much as $290 billion annually in avoidable medical spending, 13% of total U.S. healthcare spending. Research also shows that half of all patients in the U.S. do not take their medicines as prescribed, a dismal level of adherence which has held steady over the past three decades. Poor adherence leads to worsening of disease, serious and avoidable health risks, increased hospitalizations and even death. Within the study, the use of Shellpak, a proprietary calendarized 30-day, unit-of-use medication package, demonstrated improvement in the adjusted estimates of refill persistence and adherence as measured by length of therapy and proportion of days covered with medication.

"We know there are many factors affecting medication adherence, and we know that the most successful solutions will involve multiple components," said study co-author Lenn Murrelle, MSPH, PhD, and principal founder of Venebio, a life sciences research consultancy. "What's exciting about this study is that medication packaging alone was found to have a positive effect on medication refill behavior. This says to us that packaging without any additional communications or instructions to either pharmacists or patients can play an important role in helping patients take their medication as directed."

The retrospective analysis used pharmacy dispensing data from Walmart for 3.1 million individuals filling prescriptions for the generic cardiovascular medications lisinopril or enalapril, either alone or in combination with hydrochlorothiazide.

Results revealed the Shellpak refill persistence benefit was especially pronounced among certain subgroups.

  • New medication users had an average length of therapy increase of 9 days over a year.
  • Ongoing medication users had an average length of therapy increase of 5 days over a year.
  • Persons taking fixed-dose combination formulations, or 2 medications in a single tablet experienced an average 17-day increase in length of therapy for new users and 12 days for ongoing medication users.

In addition, the study revealed that Shellpak users overall were more likely to reach "full refill adherence" – at least 80% of days covered with medication in a year – than vial users, with the greatest effect observed in new medication users. However, full refill adherence (PDC greater than or equal to 80%) was more likely in Shellpak users regardless of their baseline level of adherence.

  • PDC greater than or equal to 80% was more likely reached by using Shellpak in those with the lowest level of baseline adherence, by 20% in new medication users and 23% in ongoing users.
  • Individuals with a middle level of adherence at baseline had a 15% greater likelihood of reaching full adherence with Shellpak for new users and 8% for ongoing users.
  • In the group with the highest level of baseline adherence, Shellpak users were 11% more likely to reach full adherence for new medication users and 5% for ongoing users.

"This publication is the first, large-scale pharmacoepidemiologic analysis of medication packaging, and the results are exciting and significant," said Ted Lithgow, PhD, president and chief science officer, MWV Healthcare. "We believe smarter packaging serves a purpose beyond simply containing and protecting the physical integrity of a pharmaceutical, and this robust data provides compelling scientific evidence for Shellpak as a now-proven solution to help drive better patient adherence. We will continue to work with the medical, pharmacy and pharmaceutical communities, and regulators to consider these data and to further investigate the effects of packaging on medication adherence."

About the Study

This was a two-year, retrospective cohort study of 325,361 new and ongoing users of the oral angiotensin converting enzyme inhibitors (ACEI) lisinopril or enalapril – commonly prescribed for the treatment of hypertension and congestive heart failure – designed to assess the real world effectiveness of a new calendar packaging technology on prescription refill adherence and persistence for daily, self-administered, long-term medication use. Eligible users comprised two packaging cohorts, Shellpak (282,605 lisinopril users (86.9%)) and vial (42,756 enalapril users (13.1%)), and ACEI user groups: 76.321 new users (23.5%) and 249,040 prevalent ongoing ACEI users (75.5%).  

To assess the impact of Shellpak on refill behavior, measures of refill adherence and persistence in the baseline year before and follow-up year after the packaging switch were compared in the 325,361 adults aged 18-75 years who filled 30- or 90-day prescriptions in both the baseline and follow-up years. These individuals had adherence and persistence data available both before and after the packaging switch to Shellpak. Researchers used linear and logistic regression and propensity score matching to assess the impact of calendar blister packaging on refill adherence, using medication possession ratio (MPR) and proportion of days covered (PDC), and persistence using length of therapy (LOT).

The study was designed, conducted, analyzed and reported in accordance with the Good Research Comparative Effectiveness (GRACE) principles and Guidelines for Good Pharmacoepidemiology Practice. The Walmart pharmacy dispensing data were de-identified in accordance with HIPAA guidelines.

About Shellpak®

MeadWestvaco Healthcare's Shellpak® is an innovative, award-winning package designed to improve medication adherence alone or in combination with other adherence strategies. Shellpak features a child-resistant and senior-friendly outer plastic shell that protects medication tablets packaged in a 30-day calendar blister card similar to packaging long used for birth control pills. The calendar feature helps patients track medication usage, helping reduce dosing errors such as overdosage and missed doses, and refill timing. The large, flat blistercard and package surface allows for dosing instructions and patient education to be printed in large, readable font. Shellpak can also be customized to reflect a brand image and provide differentiation for each medication enclosed.

About MWV

MeadWestvaco Corporation (NYSE: MWV), provides packaging solutions to many of the world's most- admired brands in the healthcare, beauty and personal care, food, beverage, home and garden, and tobacco industries. The company's businesses also include Consumer & Office Products, Specialty Chemicals, and the Community Development and Land Management Group, which sustainably manages the company's land holdings to support its operations, and to provide for conservation, recreation and development opportunities. With 19,000 employees worldwide, MWV operates in 30 countries and serves customers in more than 100 nations. MWV manages all of its forestlands in accordance with internationally recognized forest certification standards, and has been named to the Dow Jones Sustainability World Index for seven consecutive years. For more information, please visit

Media Contact

Pam Wheeler
tel: +1804-444-6214

SOURCE MeadWestvaco Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
(Date:11/29/2015)...  Strengthening its leadership in connected healthcare informatics, ... IntelliSpace Portal 8.0 , the latest edition of ... helps radiologists detect, diagnose and follow-up on treatment of ... North America Annual Meeting (RSNA) in ... the changing demands in radiology that result from an ...
(Date:11/29/2015)... GE Health Cloud 1 was unveiled today at the ... America (RSNA) meeting in Chicago ... ecosystem and its applications will connect radiologists and clinicians to ... – both inside and outside the hospital setting. ... the digital industrial leader, we are betting big on the ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ ... graduated from Tufts School of Dental Medicine in 1935. His father graduated from ... family being in dentistry as well as their commitment and passion to the Practice ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... National Poison Data System (NPDS) reveals that in 2014, someone called a poison ... over two million of which were human exposure cases. , The American Association ...
(Date:11/30/2015)... ... , ... Two years ago, Debbie Gregory, the CEO of, found herself ... Meditation (TM). After encouraging a number of veterans to go through the program, ... the talk. , TM is becoming one of the best alternative treatments for Post-Traumatic ...
(Date:11/30/2015)... ... ... The American Society for Clinical Pathology (ASCP) announced today that it has launched ... ASCP shared its “Give a minute. Get tested. Find a cure.” icon and infographic ... tested for HIV. , ASCP has asked members to replace their Facebook, Twitter, or ...
(Date:11/30/2015)... Beach, FL (PRWEB) , ... November 30, 2015 ... ... of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer ... and even more so for a child’s exposure limits. , The original Nov ...
Breaking Medicine News(10 mins):